NCT01571232View on ClinicalTrials.gov

Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

March 31, 2015

Conditions
Diabetic Macular EdemaNon-proliferative Diabetic RetinopathyProliferative Diabetic Retinopathy
Interventions
DRUG

dexamethasone intravitreal implant

Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)

DRUG

intravitreal bevacizumab

Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.

Trial Locations (1)

90503

Retina Macula Institute, Torrance

Sponsors

Collaborators (1)

Allergan
All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

Retina Macula Institute

OTHER